Arginine Therapy for Sickle Cell Disease Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 21, 2021

Study Completion Date

February 21, 2021

Conditions
Sickle Cell DiseaseVaso-occlusive Pain Episode
Interventions
DRUG

L-arginine

L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.

DRUG

L-arginine Loading Dose

One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg

OTHER

Placebo

Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.

Trial Locations (3)

30303

Children's Healthcare of Atlanta at Hugh Spalding, Atlanta

30322

Children's Healthcare of Atlanta at Egleston, Atlanta

30342

Children's Healthcare of Atlanta at Scottish Rite, Atlanta

Sponsors
All Listed Sponsors
collaborator

Children's Healthcare of Atlanta

OTHER

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Emory University

OTHER